Get started
Author

Tomoyo Kubo

Institution: Toranomon Hospital
ORCID: 0000-0002-2357-685X
Observed ORCID: 0000-0002-2357-685X
OpenAlex ID: A5068988384
Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies
2023 · Masashi Nishikubo, Yoshimitsu Shimomura, et al. · Blood Cancer Journal · 7
PDF
Humoral response and safety of the BNT162b2 and mRNA ‐1273 COVID ‐19 vaccines in patients with haematological diseases treated with anti‐CD20 antibodies: An observational study
2022 · Masashi Nishikubo, Yoshimitsu Shimomura, et al. · British Journal of Haematology · 7
PDF
Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study
2022 · Masashi Nishikubo, Yoshimitsu Shimomura, et al. · Journal of Infection and Chemotherapy · 5
PDF
Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide
2023 · Daishi Nakagawa, Yoshimitsu Shimomura, et al. · International Journal of Hematology · 3
Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: a case report
2022 · Tomoyo Kubo, Akihisa Hino, et al. · International Journal of Hematology · 3
Cardiac lymphoma requiring surgical resection
2022 · Tomoyo Kubo, Yoshimitsu Shimomura, et al. · eJHaem · 2
PDF
Tailoring TBI for vulnerable patients: 8 gy TBI shows comparable outcomes to 12 gy TBI in adult ALL allo-HSCT
2025 · Tomoyo Kubo, Shinsuke Takagi, et al. · Blood · 1
PDF
Comparison of methotrexate dosing protocols for graft-versus-host disease prophylaxis after unrelated hematopoietic stem cell transplantation
2024 · Naokazu Nakamura, Junya Kanda, et al. · Cytotherapy · 1
PDF
Trajectories of the SARS‐CoV ‐2 RNA load in patients with hematological malignancy
2023 · Satoshi Mitsuyuki, Masashi Nishikubo, et al. · European Journal Of Haematology · 1
Onset-subtype-dependent diagnostic performance of serum hyaluronic acid for sinusoidal obstruction syndrome/veno-occlusive disease after allogeneic hematopoietic cell transplantation
2026 · Shinsuke Takagi, Shogo Matsui, et al. · Haematologica
PDF
Favorable outcomes with fludarabine, melphalan, and total-body irradiation 8–12Gy as an intensified conditioning regimen for adult allogeneic HCT
2026 · Tomoyo Kubo, Hisashi Yamamoto, et al. · Leukemia Research
Non-germinal center diffuse large B-cell lymphoma arising from a common origin of duodenal-type follicular lymphoma
2025 · Tomoyo Kubo, Yuya Nagai, et al. · Journal of the Japan Society of the Reticuloendothelial System
PDF
Comparison of Myeloablative Conditioning with Cyclophosphamide and Total-Body Irradiation (Cy/TBI) Vs. Fludarabine, Melphalan, and Total-Body Irradiation (Flu/Mel/TBI) in Patients Undergoing Allogeneic Stem Cell Transplant for AML/ALL
2023 · Tomoyo Kubo, Hisashi Yamamoto, et al. · Blood
PDF
Booster Dose of mRNA-Based COVID-19 Vaccine Induces a Humoral and Cellular Response in Patients Recently Treated with Anti-CD20 Monoclonal Antibodies
2022 · Masashi Nishikubo, Yoshimitsu Shimomura, et al. · Blood
Risk Stratification of Diffuse Large B-Cell Lymphoma Based on Cell Surface Markers Using Flow Cytometry
2022 · Tomoyo Kubo, Yoshimitsu Shimomura, et al. · Blood
Works count: 15
Citation count: 30
H-index: 3
I10-index:
Year
Topic
Type